Ipilimumab/nivolumabColitis: 2 case reports

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2019年 / 1735卷 / 1期

关键词：

D O I：

10.1007/s40278-019-56776-7

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：160 / 160

相关论文

共 50 条

[41] Ipilimumab/nivolumabHepatitis: 2 case reports
Reactions Weekly, 2017, 1665 (1) : 164 - 164
[42] Ipilimumab/pembrolizumabHypophysitis: 2 case reports
Reactions Weekly, 2018, 1714 (1) : 242 - 242
[43] Ipilimumab/nivolumab/nivolumabColitis and lack of efficacy
Reactions Weekly, 2024, 2005 (1) : 469 - 469
[44] Ipilimumab/nivolumabColitis, hyperthyroidism and type 1 diabetes mellitus: case report
Reactions Weekly, 2018, 1705 (1) : 174 - 174
[45] Ipilimumab/pembrolizumabColitis and pneumonitis: 2 case reports
Reactions Weekly, 2017, 1633 (1) : 426 - 426
[46] Aspirin/ipilimumab/pembrolizumabColitis: 2 case reports
Reactions Weekly, 2019, 1745 (1) : 66 - 66
[47] Ipilimumab/nivolumabVarious toxiciites: 2 case reports
Reactions Weekly, 2018, 1702 (1) : 142 - 142
[48] Ipilimumab/nivolumab/pembrolizumabTrabeculitis: 2 case reports
Reactions Weekly, 2022, 1933 (1) : 253 - 253
[49] Ipilimumab/nivolumab/pembrolizumabPneumonitis: 2 case reports
Reactions Weekly, 2022, 1917 (1) : 327 - 327
[50] Ipilimumab/nivolumabVarious toxicities: 2 case reports
Reactions Weekly, 2017, 1676 (1) : 175 - 175

← 1 2 3 4 5 →